SCHEMBL2286282

SCHEMBL2286282

O=C(F)C1(C(=O)Nc2ccc(F)cc2)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.48
GAA P10253 1/20 0.47
MET P08581 6/20 0.47
HDAC1 Q13547 1/20 0.47
EGFR P00533 2/20 0.46
TGM2 P21980 1/20 0.44
FAAH O00519 1/20 0.44
RET P07949 2/20 0.44
KIT P10721 2/20 0.44
AXL P30530 2/20 0.44
KDR P35968 2/20 0.44
FLT3 P36888 2/20 0.44
KMT2A Q03164 2/20 0.44
AURKA O14965 1/20 0.44
RIPK2 O43353 1/20 0.44
ABCB11 O95342 1/20 0.44
ABL1 P00519 1/20 0.44
ERBB2 P04626 1/20 0.44
NTRK1 P04629 1/20 0.44
LCK P06239 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12468984 0.91 ALDH1A1 (0.53) ALDH1A1GAAMETHDAC1EGFR
SCHEMBL105644 0.86 ALDH1A1 (0.48) ALDH1A1GAAMETHDAC1EGFR
SCHEMBL26178871 0.84 ALDH1A1 (0.47) ALDH1A1GAAMETHDAC1EGFR
SCHEMBL4398555 0.84 GAA (0.53) ALDH1A1GAAMETHDAC1EGFR
SCHEMBL903072 0.84 MET (0.47) ALDH1A1GAAMETHDAC1EGFR
SCHEMBL23982911 0.84 ALDH1A1 (0.47) ALDH1A1GAAMETHDAC1EGFR
SCHEMBL407809 0.84 ALDH1A1 (0.56) ALDH1A1GAAMETHDAC1EGFR
SCHEMBL13271309 0.84 ALDH1A1 (0.50) ALDH1A1GAAMETHDAC1EGFR
SCHEMBL2280125 0.84 MET (0.47) ALDH1A1GAAMETHDAC1EGFR
SCHEMBL558092 0.84 POLB (0.55) METEGFRFAAHAXLKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8003662-B2 Heterobicyclic thiophene compounds and methods of use ARRAY BIOPHARMA, INC. (US) 2011-08-23 US disclosed
US-20100256356-A1 HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE ARRAY BIOPHARMA INC. (US) 2010-10-07 US disclosed
US-7723330-B2 Heterobicyclic pyrazole compounds and methods of use ARRAY BIOPHARMA INC. (US) 2010-05-25 US disclosed
EP-2001880-A2 HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE Array Biopharma, Inc. (US) 2008-12-17 EP disclosed
EP-1989211-A2 HETEROBICYCLIC THIOPHENE COMPOUNDS FOR THE TREATMENT OF CANCER Array Biopharma, Inc. (US) 2008-11-12 EP disclosed
WO-2008063202-A2 HETEROBICYCLIC THIOPHENE COMPOUNDS FOR THE TREATMENT OF CANCER ARRAY BIOPHARMA INC. (US) 2008-05-29 WO disclosed
US-20070238726-A1 Heterobicyclic pyrazole compounds and methods of use GENENTECH, INC. 2007-10-11 US disclosed
WO-2007103308-A2 HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE ARRAY BIOPHARMA INC. (US) 2007-09-13 WO disclosed
US-20070197537-A1 Heterobicyclic thiophene compounds and methods of use ARRAY BIOPHARMA, INC. 2007-08-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197537-A1 Heterobicyclic thiophene compounds and methods of use ERBB2, LCK, SRC ALDH1A1 1635/4885GAA 1103/4885MET 142/4885
US-20100256356-A1 HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE ROR1, CYP11B1, CYP11B2 ALDH1A1 1929/4885GAA 2295/4885MET 357/4885
US-20070238726-A1 Heterobicyclic pyrazole compounds and methods of use ROR1, CYP11B1, CYP11B2 ALDH1A1 1929/4885GAA 2295/4885MET 357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.